JAMA Oncol 7 (4): 573-584, 2021.[PUBMED Abstract] Murthy RK, Loi S, Okines A, et al.: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
N Engl J Med 382 (7): 597-609, 2020.[PUBMED Abstract] Saura C, Oliveira M, Feng YH, et al.: Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With â‰¥ 2 HER2-Directed Regimens: Phase III NALA Trial.
J Clin Oncol 38 (27): 3138-3149, 2020.[PUBMED Abstract] Geyer CE, Forster J, Lindquist D, et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer.